OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	83.37	110.76	29.88	11.54
Cash & Short-Term Investments	83.37	110.76	29.88	11.54
Cash Growth	347.45%	270.74%	158.82%	-
Prepaid Expenses	1.18	2.24	3.89	2.08
Total Current Assets	84.55	113	33.77	13.62
Property, Plant & Equipment	1.4	1.8	1.91	2.05
Other Long-Term Assets	0.12	0.11	0.06	0.33
Total Assets	86.07	114.91	35.73	16
Accounts Payable	2.38	2.97	3.42	2.52
Accrued Expenses	4.66	7.03	3.66	2.87
Current Portion of Leases	0.56	0.54	0.21	0.15
Total Current Liabilities	7.6	10.53	7.29	5.54
Long-Term Leases	0.27	0.55	0.47	0.49
Total Liabilities	7.9	11.08	7.75	6.03
Common Stock	0	0	-	0
Additional Paid-In Capital	264.2	258.55	0.21	2.66
Retained Earnings	-186.04	-154.72	-102.05	-57.07
Total Common Equity	78.17	103.83	-101.84	-54.42
Shareholders' Equity	78.17	103.83	27.98	9.97
Total Liabilities & Equity	86.07	114.91	35.73	16
Total Debt	0.82	1.09	0.67	0.64
Net Cash (Debt)	82.55	109.68	29.2	10.91
Net Cash Growth	576.54%	275.58%	167.76%	-
Net Cash Per Share	8.24	31.82	102.89	-
Filing Date Shares Outstanding	13.51	13.44	13.34	-
Total Common Shares Outstanding	13.51	13.35	13.34	-
Working Capital	76.96	102.47	26.48	8.08
Book Value Per Share	5.79	7.78	-7.63	-
Tangible Book Value	78.17	103.83	-101.84	-54.42
Tangible Book Value Per Share	5.79	7.78	-7.63	-
Machinery	-	1.05	1.01	0.85
Leasehold Improvements	-	1.09	1.09	1

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q